NASDAQ OMX

Atea Pharmaceuticals Reports Positive Proof of Concept Clinical Data With AT-527 for the Treatment of Chronic Hepatitis C

Dela
  • AT-527 is a novel pan-genotypic purine nucleotide prodrug NS5B polymerase inhibitor which has been safe and well tolerated in this ongoing multiple part trial 
  • AT-527 exhibits potent antiviral activity in genotype (GT)-1b and GT-3 hepatitis C virus (HCV) infected patients with once-daily (QD) dosing of 550 mg for 7-days 
  • Preliminary data suggest that AT-527 has potent and equivalent antiviral activity in both cirrhotic and non-cirrhotic (NC) HCV-infected patients

BOSTON, April 12, 2018 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc., a biopharmaceutical company engaged in the development of next-generation therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections, today reported positive data from its ongoing clinical trial of AT-527 in patients with GT-1b and GT-3 HCV infection. The company will present the data today at The International Liver Congress(TM) 2018 sponsored by the European Association for the Study of the Liver taking place in Paris, France.   

"Although the introduction of new therapies has improved cure rates in recent years, hepatitis C continues to represent a serious global health burden, particularly within more difficult-to-treat patient populations. Given the limitations of currently available agents, we are very excited about the emerging clinical profile of AT-527, a novel, highly differentiated purine nucleotide prodrug, which has an attractive safety profile and very significant antiviral potency.  Most notably, preliminary data indicate that AT-527 exhibits potent antiviral activity, regardless of genotype or cirrhosis status in HCV-infected subjects," stated Jean-Pierre Sommadossi, PhD, Atea's Founder, Chairman and Chief Executive Officer.  

Poster No. THU-341

Title:   AT-527, a pan-genotypic purine nucleotide prodrug, exhibits potent antiviral activity in subjects with chronic hepatitis C

Date/Time:   Thursday, April 12, 2018; 9:00 am - 5:00 pm CET

A summary of the data to be presented shows a mean maximum HCV RNA reduction of 2.3 log10 IU/mL after a single dose, and 4.4 log10 IU/mL after 7 days of dosing, of AT-527 in NC GT-1b HCV-infected subjects.  A mean reduction of 2.4 log10 IU/mL after first dose and 4.6 log10 IU/mL after 7 days of dosing was achieved in NC GT-3 HCV-infected subjects, respectively.  In ongoing cohorts, antiviral activity in Child Pugh A cirrhotic GT-1b/3 HCV infected subjects was similar to NC GT-1b and NC GT-3 cohorts.  Emax modeling confirms the clinical observation that 550 mg AT-527 QD will produce maximum efficacy.  No serious adverse events, dose-limiting toxicities or premature discontinuations were observed.

About the Trial

The five part study commenced patient enrollment in 2017, and was designed to assess the safety and efficacy of single and multiple doses of AT-527 in healthy and HCV-infected subjects.  All HCV-infected subjects were treatment-naïve with HCV RNA greater than or equal to 5 log10 IU/mL.  The objectives of the study were to assess safety/tolerability, pharmacokinetics (PK) and antiviral activity.

The trial evaluated single oral doses up to 367 mg (400 mg salt form) in healthy subjects (Part A), single doses up to 550 mg (600 mg salt form) in NC GT-1b HCV-infected subjects (Part B) and multiple doses up to 550 mg once-daily (QD) for 7 days in NC GT-1b HCV-infected subjects (Part C).  Ongoing cohorts are evaluating 550 mg QD for 7 days in NC GT-3 (Part D) and Child Pugh A cirrhotic GT-1b/3 (Part E) HCV-infected subjects.  Plasma levels of AT-273, the nucleoside metabolite of the active triphosphate, were measured using LC-MS/MS; HCV RNA was quantified using COBAS® AmpliPrep/TaqMan® HCV Test v2.0 with a limit of quantitation (LOQ) of 15 IU/mL.

About AT-527

AT-527, a proprietary investigational agent discovered at Atea, is the salt form of a purine nucleotide prodrug NS5B polymerase inhibitor.  Unique structural modifications of AT-527 result in differentiated pharmacologic and antiviral properties as compared to other anti-HCV nucleotides.  AT-511, the free base of AT-527, showed potent antiviral activity in vitro against wild-type clinical isolates with EC95   values less than 80 nM in all HCV genotypes, and demonstrated about 10- to 14-fold more potency than sofosbuvir (SOF) in GT-1 and GT-3 replicons.  AT-511 maintained activity against SOF-resistant S282T single and S282T/L159F double variants, with about 50-fold greater potency than SOF.  

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and is a leading cause of chronic liver disease and transplants.  According to the World Health Organization, over 70 million people suffer from chronic hepatitis C. Direct-acting antiviral agents (DAAs) have markedly improved the prognosis of many patients infected with the hepatitis C virus and allow the achievement of a cure in 8 - 12 weeks in select patient populations.  Further shortening of the treatment duration in those patients and extending it to more difficult-to-treat HCV patient populations continues to be a sought-after goal of the biotech and pharma industry.  Global sales of DAAs for the treatment of HCV infection were $12.5 billion in 2017. 

About Atea
Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in the discovery and development of proprietary and novel therapeutics for the treatment of hepatitis C and other single stranded RNA viral infections. Atea was founded in 2013 by its Chairman and Chief Executive Officer Jean-Pierre Sommadossi, PhD, and is headquartered in Boston, MA.

Contact:

Company:
Andrea J. Corcoran
617-669-4272
corcoran.andrea@ateapharma.com

Investors and Media:
Constantine Davides
Westwicke Partners
Tel: 339-970-2846
constantine.davides@westwicke.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Atea Pharmaceuticals, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Forterra Announces First Quarter 2018 Earnings Schedule24.4.2018 12:00Pressmeddelande

IRVING, Texas, April 24, 2018 (GLOBE NEWSWIRE) -- Forterra, Inc. ("Forterra") (Nasdaq:FRTA) plans to release first quarter 2018 financial results before the market open on Tuesday, May 8, 2018. A conference call to review financial results will also be held on Tuesday, May 8, 2018 at 8:30 a.m. Eastern time (7:30 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q1 2018 Forterra, Inc. Earnings Call Date: Tuesday, May 8, 2018 Time: 8:30 a.m. Eastern Time (7:30 a.m. Central) https://edge.media-server.com/m6/p/a3wzhe79 Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Participant Passcode: 6398379 Replay Information A replay of the conference call and archive of the webcast will be available within 24 hours after the call on the "Events & Presentations" page under the Investor section of the Company's w

Meltwater acquires leading social analytics company Sysomos24.4.2018 10:00Pressmeddelande

Acquisition expands Meltwater's ability to incorporate online news and data with social media analytics in one robust platform SAN FRANCISCO, April 24, 2018 (GLOBE NEWSWIRE) -- Meltwater, a pioneer of media intelligence and now Outside Insight, today announced its acquisition of Sysomos, a leader in social analytics and engagement. The addition of Sysomos to Meltwater enables organizations to analyze social media, news and other human-generated content in one platform, furthering Meltwater's mission to give businesses the insights from outside data, helping them stay ahead. "All the social analytics companies look at social data in isolation, limiting the insights for brands and businesses," says Jorn Lyseggen, founder and CEO of Meltwater. "With our acquisition of Sysomos, we can bring together news and social media under one company, giving social data context while adding social engagement to our news and media monitoring offering." For the PR and communications teams who engage wit

New leaders emerge in 2018 All-Europe trading team ranking24.4.2018 10:00Pressmeddelande

NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- Competition in electronic trading is becoming fierce as global trade execution teams re-position themselves for delivering their solutions at scale in a post MiFID II regulatory environment. J.P. Morgan continues to dominate claiming first place in electronic trading, for a second consecutive year, according to Institutional Investor's All-Europe Trading Team survey. Meanwhile Bank of America Merrill Lynch took home second place, up two spots from fourth place last year; a significant move for Bank of America Merrill Lynch, which bumped its peers Credit Suisse in third place and UBS in fourth place to win the No. 2 position. The two-rung move is a marked shift away from its previous high-touch leadership and is an endorsement that the bank's investments in technology are resonating with clients. In high-touch trading, UBS leapt to No. 1 swapping its fifth place position last year with Bank of America Merrill Lynch, who took fifth in the high

BT Dials in Corvil Analytics to Help Achieve World-Class Service Delivery for World's Largest Virtual Contact Centre24.4.2018 10:00Pressmeddelande

Corvil empowers BT with the visibility and insight to achieve outstanding caller experience for a public sector customer serving 20M+ citizens DUBLIN, Ireland, April 24, 2018 (GLOBE NEWSWIRE) -- Corvil today announced that BT Global Services has deployed Corvil Analytics to manage and optimise VoIP call quality of one of the largest contact centres in the world channelling its services through 30,000 agents across 180 sites. As a leading provider of contact centre solutions globally, BT has a strong track-record in designing and implementing large-scale transformational engagements. Looking to simplify service assurance and maintain call quality excellence in an environment where call volumes continually reach 12500 concurrent calls (12 new calls per second), BT sought to enlist an analytics partner. In a climate of intense scrutiny on public sector performance and with stringent customer Service Level Agreements (SLAs) in place, BT selected Corvil to help improve caller experience by

MedicCoin Unveils International Adoption Strategy Based on Integrating Blockchain Technology into Everyday Life24.4.2018 09:00Pressmeddelande

Strategy focuses on improving health of mankind through blockchain-powered rewards, advancing scientific research and charitable donations NEW YORK, April 24, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- MedicCoin, a community-driven crypto focused on improving the lives of millions worldwide, today provides the multifaceted roadmap established for global adoption while recapping practical innovations that set MedicCoin apart for everyday use. Introducing Multiple Ways to Earn Crypto as a Reward for Positive Choices The MedicCoin founders envisioned using blockchain technology to make life better for all mankind. A key part of staying true to this vision is ensuring people around the world can join the MedicCoin community without highly technical skills or expensive mining equipment. Living an Active Lifestyle By simply installing the MedicWalk app and staying active, anyone will be able to acquire MedicCoin. MedicWalk will be launched within the next few weeks. Donating Unused Computer

In-Memory Computing Summit Europe Announces Full Breakout Session Schedule24.4.2018 09:00Pressmeddelande

Register by April 29th to Receive a 30 Percent Discount FOSTER CITY, Calif., April 24, 2018 (GLOBE NEWSWIRE) -- GridGain Systems, provider of enterprise-grade in-memory computing platform solutions based on Apache® Ignite(TM), today released the full breakout session schedule for the second annual In-Memory Computing Summit® Europe, the premier conference for individuals from Europe and Asia that are currently using or exploring using in-memory computing. Conference breakout sessions are in five tracks: Tales from the Trenches, New Capabilities, Architecture, Streaming Data, and Hardware. Speakers include representatives from companies such as Oracle, Intel, NEC Corporation of America, GridGain Systems, Hazelcast, iguazio, Neeve Research, ScaleOut Software, Software AG, Bouquet.ai, and VoltDB. The IMC Summit Europe will take place at the Park Plaza Victoria London, June 25-26, 2018. Attendees can receive a 30 percent Super Saver discount off the full price registration fee by purchasin

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum